PHASE 1 FIRST-IN-HUMAN STUDY OF AUR112, A HIGHLY SELECTIVE MALT1 INHIBITOR, IN RELAPSED LYMPHOID MALIGNANCIES (EHA 2026) - May 12, 2026 - Abstract #EHA-3719; PS2056; Pres time: Jun 13, 2026; 06:45 PM - 07:45 PM; Location: Hall A; P1 | "Proc. AACR 2023; Abstract C127"
First-in-human • IO biomarker • P1 data • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Extranodal Marginal Zone Lymphoma • Follicular Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Lymphoplasmacytic Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Neutropenia • Non-Hodgkin's Lymphoma • T Cell Non-Hodgkin Lymphoma • Waldenstrom Macroglobulinemia • CARD11 • IL2 • MALT1
|
|
Suchit Kumbhare 1; Suresh Oduru 1; Manjunath Krishnappa 1; Nirbhary Tiwari 1; Lavanya Krishna 1; Saravanan Thiyagarajan 1; Divya Adiga 1; Sourav Kumar Mishra 2; Manoj Toshniwal 3; Vinod Patil 4; Pradnya Modak 5; Shashikant Janardan Apte 6; Uttam Kumar Nath 7; Lakshmaiah K.C. 8; Akash Kumar 9; Aniket Mohite 10; Murali Ramachandra 1; Akhil Kumar1
|